Randomized-controlled Trial (RCT) on CPAP-withdrawal and Microvascular Function in OSA
Not Applicable
Completed
- Conditions
- Obstructive Sleep Apnoea
- Interventions
- Other: CPAP therapy withdrawalProcedure: Continue CPAP treatment
- Registration Number
- NCT01797653
- Lead Sponsor
- University of Zurich
- Brief Summary
Randomized controlled trial (therapeutic vs. placebo CPAP) including 46 patients with obstructive sleep apnea (OSA) to define the physiological effects of continuous positive airway pressure (CPAP) therapy withdrawal on myocardial perfusion and dermal and renal microvascular function during a 2 week period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo CPAP CPAP therapy withdrawal patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks. therapeutic CPAP Continue CPAP treatment patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
- Primary Outcome Measures
Name Time Method hyperaemic myocardial blood flow 2 weeks
- Secondary Outcome Measures
Name Time Method Coronary flow reserve 2 weeks Coronary flow reserve determined by PET
Urine albumine excretion rate 2 weeks Dermal microvascular vasodilatory response 2 weeks
Trial Locations
- Locations (1)
University Hospital Zurich, Division of Pneumology
🇨ðŸ‡Zurich, ZH, Switzerland